
MTHERA PHARMA is a South Korean biopharmaceutical R&D company established in 2020, specializing in multi-component and multi-targeting (MCMT) approaches and cutting-edge CMC technology. The company focuses on developing new medicines for chronic diseases, leveraging collaborations with world-renowned Korean scholars. Its pipeline includes treatments for Parkinson's disease and other chronic conditions, with clinical trials progressing in the US. MTHERA PHARMA has received multiple awards for technological innovation and patents, and it operates an R&D center in Seoul. The company aims to be a global pharmaceutical R&D leader by pursuing health and happiness through innovative drug development.

MTHERA PHARMA is a South Korean biopharmaceutical R&D company established in 2020, specializing in multi-component and multi-targeting (MCMT) approaches and cutting-edge CMC technology. The company focuses on developing new medicines for chronic diseases, leveraging collaborations with world-renowned Korean scholars. Its pipeline includes treatments for Parkinson's disease and other chronic conditions, with clinical trials progressing in the US. MTHERA PHARMA has received multiple awards for technological innovation and patents, and it operates an R&D center in Seoul. The company aims to be a global pharmaceutical R&D leader by pursuing health and happiness through innovative drug development.